类风湿关节炎应用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗的效果研究  

Therapeutic effect of recombinant human tumor necrosis factor receptor antibody fusion protein on rheumatoid arthritis

作　　者：李芳[1,2] 姚建华[1,2] 闫永龙 林玮[1,2] 宁晓然[1,2] 曹京旌 LI Fang;YAO Jianhua;YAN Yonglong;LIN Wei;NING Xiaoran;CAO Jingjing(Department of Rheumatism,Hebei People＇s Hospital,Hebei 050051,China;Geriatric Department of the Second Hospital of Hebei Medical University,Hebei 050000,China)

机构地区：[1]河北省人民医院风湿科,050051 [2]河北医科大学第二医院老年科,050000

出　　处：《国际检验医学杂志》2018年第A01期52-54,共3页International Journal of Laboratory Medicine

基　　金：河北省医学科学研究重点课题计划（20090214）.

摘　　要：目的 探讨注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白运用在风湿免疫疾病治疗中的临床价值。 方法 选择2010年1月至2012年1月期间我院风湿免疫科收治的120例类风湿关节炎（RA）患者为研究对象，根据数字随机法将其分为两组，其中对照组接受常规治疗，而观察组则运用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗，对两组效果进行比较分析。 结果 治疗前，两组的HAQ和VAS评分比较无差异（ P 〉0.05）；治疗后，与对照组比较，观察组的VAS和HAQ评分改善明显，组间对比差异显著（ P 〈0.05）；观察组的不良反应发生率低于对照组（ P 〈0.05）；同时，两组的类风湿因子、红细胞沉降率、CRP、肿胀关节数以及压痛关节数比较有统计学意义（ P 〈0.05）。 结论 临床上给予类风湿关节炎患者注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗效果显著。Objective： To investigate the clinical value of recombinant human tumor necrosis factor receptor-antibody fusion protein for injection in the treatment of rheumatic immune diseases. Methods ： 120 patients with rheumatoid arthritis （RA） from January 2010 to January 2012 were randomly divided into two groups.The observation group was treated with recombinant human tumor necrosis factor receptor-antibody fusion protein for injection. Results： Before treatment,there was no difference in HAQ and VAS scores between the two groups.After treatment,the scores of VAS and HAQ in the observation group were significantly improved than those in the control group （ P 〈0.05）,the incidence of adverse reactions in the observation group was lower than that in the control group （ P 〈0.05）,and the rheumatoid factors in the two groups were significantly higher than those in the control group （ P 〈0.05）.The erythrocyte sedimentation rate and CRP,the number of swollen joints and the number of tenderness joints were significantly different （ P 〈0.05）. Conclusion： The therapeutic effect of recombinant human tumor necrosis factor receptor-antibody fusion protein for injection in patients with rheumatoid arthritis is remarkable.

关 键 词：注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 类风湿关节炎 

分 类 号：R735.7[医药卫生—肿瘤]